Phase III clinical trial is evaluating RenovoGem™ for the treatment of Locally Advanced Pancreatic Cancer UNMC opened enrollment of TIGeR-PaC…
• ONP-002 stability eliminates need for cumbersome cold storage• No FDA-approved pharmaceutical treatment available for concussion SARASOTA, Fla., Aug. 14,…
Company reviews goals and significance of the study and outlines development strategy in Mild Cognitive Impairment due to Alzheimer’s diseaseROCHESTER,…
Company focused on execution of lead program GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) GRI-0621 interim data readout…
Declared development candidate MGX-001 for the treatment of hemophilia A; plans to present 12-month NHP durability study data in September…
PEMGARDA™ launched commercially in Q2 2024 with $2.3 million of net product revenueNotable acceleration of commercial results in early Q3…
WILMETTE, Ill., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing…
Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J., Aug. 14, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:…
Initiated Phase 2b trial of VYN201 in nonsegmental vitiligo, with top-line results expected in mid-2025Phase 1a SAD/MAD trial of VYN202…
Applauds first FDA approval of non-injection-based epinephrine deviceReiterates expected timing for filing of New Drug Application (NDA) for Anaphylm™ (epinephrine)…